Alexander I. Spira, MD, PhD, FACP

Position

Medical Oncologist

Board Certification

Medical Oncology and Internal Medicine

Fellowship

Johns Hopkins Hospital, Medical Oncology

Internship

Hospital of the University of Pennsylvania

Residency

Hospital of the University of Pennsylvania

Medical School

New York University School of Medicine

College

Harvard University

Special Interests

Thoracic, sarcomas, clinical trials

Alexander I Spira, MD, PhD, FACP

Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins

Dr. Alexander Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York School of Arts and Sciences.

As Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is also Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine, and serves as Assistant Professor of Oncology.

Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.

Physician Videos:

Physician Publications

July 13, 2022

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

June 3, 2022

ASCO 2022 | KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC

June 3, 2022

Adagrasib Induces Promising Efficacy, Deep Responses in KRAS G12C NSCLC

June 3, 2022

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

June 3, 2022

KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients

June 3, 2022

Dr. Spira on the Potential Role of Adagrasib in NSCLC

April 8, 2022

Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

March 15, 2022

Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study

December 1, 2021

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

December 1, 2021

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

October 18, 2021

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer

September 13, 2021

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

August 2, 2021

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

July 1, 2021

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

July 1, 2021

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

May 24, 2021

Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational study

May 3, 2021

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies

May 1, 2021

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

February 25, 2021

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

January 29, 2021

Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer

January 29, 2021

Datopotamab Deruxtecan Elicits Early Antitumor Activity in Relapsed/Refractory Metastatic NSCLC

December 26, 2020

Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)

September 1, 2020

Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cance

August 11, 2020

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

June 7, 2020

Camidanlumab Tesirine, an Antibody-Drug Conjugate, in Relapsed/Refractory CD25-positive Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia: A Phase I Study

April 7, 2020

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue SarcomasThe ANNOUNCE Randomized Clinical Trial

March 21, 2020

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

October 1, 2019

A review of canakinumab and its therapeutic potential for non-small cell lung cancer.

August 1, 2019

Detection of NRG1 Gene Fusions in Solid Tumors.

August 1, 2019

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

September 25, 2018

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

March 9, 2016

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

September 14, 2015

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

June 3, 2013

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

February 1, 2013

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

January 2, 2013

Expert Insight: Adjuvant Therapy Fails for High-Risk Soft Tissue Sarcoma

June 1, 2012

Phase II study of two eribulin regimens in combination with erlotinib in patients (pts) with previously treated advanced non-small cell lung cancer

April 16, 2012

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

January 1, 2012

Clinical trial design in the age of molecular profiling.

September 8, 2011

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

June 1, 2011

Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients

June 1, 2011

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

June 1, 2011

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

December 4, 2010

Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma.

December 1, 2010

Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.

December 3, 2009

Use of an ex vivo multiplexed signal pathway inhibitor treatment to reveal sensitivity of myeloma and nonmyeloma bone marrow cell populations.

December 1, 2009

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.

January 22, 2004

Multidisciplinary Management of Lung Cancer

January 1, 2002

The use of Chemotherapy in Soft Tissue Sarcomas

Clinical Trial 22049

A PHASE 1B/2, OPEN-LABEL, SAFETY, TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Clinical Trial INBRX-106

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Clinical Trial 23and ME

"A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies"

Clinical Trial 21385

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Clinical Trial 61186372NSC3004

A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

Clinical Trial TSC-007

A Phase 2 multi-center open-label basket trial of ABI-009 (nab-sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

All Clinical Trials for Alexander I. Spira, MD, PhD, FACP

Clinical Trial 22049

Locations:

ClinicalTrials.gov ID:

NCT05572684

ClinicalTrials.gov Link:

Clinical Trial INBRX-106

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04198766

ClinicalTrials.gov Link:

Clinical Trial 23and ME

“A Phase 1, Multicenter, Open-Label, Dose-Escalation and
Expansion Study of Intravenously Administered 23ME-00610
in Patients with Advanced Solid Malignancies”

Locations:

ClinicalTrials.gov ID:

NCT05199272

ClinicalTrials.gov Link:

Clinical Trial 21385

Locations:

ClinicalTrials.gov ID:

NCT04813627

ClinicalTrials.gov Link:

Clinical Trial 61186372NSC3004

Locations:

ClinicalTrials.gov ID:

NCT05388669

ClinicalTrials.gov Link:

Clinical Trial TSC-007

A Phase 2 multi-center open-label basket trial of ABI-009 (nab-sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Locations:

ClinicalTrials.gov ID:

NCT05103358

ClinicalTrials.gov Link:

Clinical Trial TWT-203

PHASE 1b/2 DOSE-CONFIRMING, MULTIPART, MULTICENTER STUDY OF CFI-402257 AS A SINGLE AGENT IN ADVANCED SOLID TUMORS AND IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER AFTER DISEASE PROGRESSION ON PRIOR CDK4/6 AND ENDOCRINE THERAPY

Locations:

ClinicalTrials.gov ID:

NCT05251714

ClinicalTrials.gov Link:

Clinical Trial U31402-A-U301

” A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy”

Locations:

ClinicalTrials.gov ID:

NCT05338970

ClinicalTrials.gov Link:

Clinical Trial 516-014

A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies

Locations:

Clinical Trial NAV-1104

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

Locations:

ClinicalTrials.gov ID:

NCT05375084

ClinicalTrials.gov Link:

Clinical Trial JBI-802-101

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05268666

ClinicalTrials.gov Link:

Clinical Trial FURMO

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

Locations:

ClinicalTrials.gov ID:

NCT05364073

ClinicalTrials.gov Link:

Clinical Trial DR-01-ONC-001

A Multicenter, Open-Label, First-in-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Locations:

ClinicalTrials.gov ID:

NCT05475925

ClinicalTrials.gov Link:

Clinical Trial ASP3082

A Phase I Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D

Locations:

ClinicalTrials.gov ID:

NCT05382559

ClinicalTrials.gov Link:

Clinical Trial SGN-ALPV-001

A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05229900

ClinicalTrials.gov Link:

Clinical Trial VS-6766-204

A Phase 1/2 Study of VS-6766 in Combination with Adagrasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer

Locations:

ClinicalTrials.gov ID:

NCT05375994

ClinicalTrials.gov Link:

Clinical Trial RMC-6291-001

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRAS G12C Mutant Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05462717

ClinicalTrials.gov Link:

Clinical Trial H002-101

A Phase 1/2a, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-Tumor Activity of H002 in Patients with Active Epidermal Growth Factor Receptor Mutation Locally Advanced or Metastatic Non-Small Lung Cancer

Locations:

Clinical Trial IO-202-CL-002

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05309187

ClinicalTrials.gov Link:

Clinical Trial ASN004

An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy with Advanced Malignant Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT04410224

ClinicalTrials.gov Link:

Clinical Trial XTX101

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients with Advanced Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT04896697

ClinicalTrials.gov Link:

Clinical Trial NUV-868

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination with Olaparib or Enzalutamide in Adult Patients with Advanced Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT05252390

ClinicalTrials.gov Link:

Clinical Trial PEEL-224

An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT05329103

ClinicalTrials.gov Link:

Clinical Trial ERAS-007-04

A Phase 1b/2 Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Hematologic Malignancies (HERKULES-4).

Locations:

ClinicalTrials.gov ID:

NCT05279859

ClinicalTrials.gov Link:

Clinical Trial AZD8701

A Phase 1 First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvalumab (MEDI4736) in Participants with Advanced Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT04504669

ClinicalTrials.gov Link:

Clinical Trial SPX-101

A Phase 1, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of an Anti-Claudin 18.2 Antibody SPX-101 in Patients with Advanced or Refractory Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05231733

ClinicalTrials.gov Link:

Clinical Trial RMC-6236

Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS.

Locations:

ClinicalTrials.gov ID:

NCT05379985

ClinicalTrials.gov Link:

Clinical Trial BNT142-01

First-in-Human, Open-Label, Mulitcenter, Phase 1/2a, Dose Escalation Trial with Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients with CLDN6-Positive Advanced Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT05262530

ClinicalTrials.gov Link:

Clinical Trial XMT-1660

A Phase 1b, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05377996

ClinicalTrials.gov Link:

Clinical Trial DZ2019E0001

A Phase 1/2, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

Locations:

ClinicalTrials.gov ID:

NCT03974022

ClinicalTrials.gov Link:

Clinical Trial 21498

A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)

Locations:

ClinicalTrials.gov ID:

NCT05074810

ClinicalTrials.gov Link:

Clinical Trial 21308

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN‑c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer

Locations:

ClinicalTrials.gov ID:

NCT05198804

ClinicalTrials.gov Link:

Clinical Trial 21239

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Locations:

ClinicalTrials.gov ID:

NCT04988295

ClinicalTrials.gov Link:

Clinical Trial 20388

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

Locations:

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Clinical Trial 20386

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

Locations:

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Clinical Trial 20382

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

Locations:

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Clinical Trial DS1062-A-U104

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab with or without Platinum Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) (Phase 1b Study of Dato-DXd in Combination with Durvalumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer

Locations:

ClinicalTrials.gov ID:

NCT04612751

ClinicalTrials.gov Link:

Clinical Trial D967YC00001

A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+)

Locations:

ClinicalTrials.gov ID:

NCT04686305

ClinicalTrials.gov Link:

Clinical Trial 47MAB-ADVCA-101

A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Subjects with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04900519

ClinicalTrials.gov Link:

Clinical Trial GO-010

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer

Locations:

ClinicalTrials.gov ID:

NCT05141721

ClinicalTrials.gov Link:

Clinical Trial ERAS-007-02

Phase 1b/2, Open-Label, Multicenter Study of ERAS-007 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Non-Small-Cell Lung Cancer (HERKULES-2)

Locations:

ClinicalTrials.gov ID:

NCT04959981

ClinicalTrials.gov Link:

Clinical Trial BT7480-100

Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies

Locations:

ClinicalTrials.gov ID:

NCT05163041

ClinicalTrials.gov Link:

Clinical Trial RBS2418

A First-in-Human, Phase 1a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizuamab in Subjects with Advanced Unresectable, Recurrent Metastatic Tumors.

Locations:

ClinicalTrials.gov ID:

NCT05270213

ClinicalTrials.gov Link:

Clinical Trial BBP-398

A Phase 1 Study of the SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

Locations:

ClinicalTrials.gov ID:

NCT04528836

ClinicalTrials.gov Link:

Clinical Trial BIO-106

A Phase 1/2 Study of BIO-106 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Cancers (Starbridge-1)

Locations:

ClinicalTrials.gov ID:

NCT05320588

ClinicalTrials.gov Link:

Clinical Trial CF33-hNIS

A Phase 1, Dose Escalation, Safety, and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors

Locations:

Clinical Trial TNG908-C101

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-Tumor Activity of TNG908 in Patients with MTAP-Deleted Advanced or Metatstatic Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT05275478

ClinicalTrials.gov Link:

Clinical Trial PRT2527-01

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT2527 in Patients with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05159518

ClinicalTrials.gov Link:

Clinical Trial AN4005

An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors

Locations:

ClinicalTrials.gov ID:

NCT04999384

ClinicalTrials.gov Link:

Clinical Trial NUV-422-04

A Phase 1b/2 Safety and Efficacy Study of NUV-422 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Locations:

ClinicalTrials.gov ID:

NCT05191017

ClinicalTrials.gov Link:

Clinical Trial NUV-422-03

Randomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive Epidermal Growth Factor Receptor2-Negative (HR+ HER2-) Advanced Breast Cancer

Locations:

ClinicalTrials.gov ID:

NCT05191004

ClinicalTrials.gov Link:

Clinical Trial SET-101

A Phase 1/1b, Open-Label Multi Center Two Part Study of SETD2 Inhibitor EZM414 in Subjects with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Locations:

ClinicalTrials.gov ID:

NCT05121103

ClinicalTrials.gov Link:

Clinical Trial PY314-1-101

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04691375

ClinicalTrials.gov Link:

Clinical Trial BDTX-1535

A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

Locations:

ClinicalTrials.gov ID:

NCT05256290

ClinicalTrials.gov Link:

Clinical Trial BLU-451-1

A Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations

Locations:

ClinicalTrials.gov ID:

NCT05241873

ClinicalTrials.gov Link:

Clinical Trial INBRX-209

A Randomized, Blinded, Placebo-Controlled, Phase 2 Study of INBRX-109 in Unrsectable or Metastatic Conventional Chondrosarcoma

Locations:

ClinicalTrials.gov ID:

NCT04950075

ClinicalTrials.gov Link:

Clinical Trial CLN-619-001

A Phase 1 Dose Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05117476

ClinicalTrials.gov Link:

Clinical Trial Onc-392-001

Safety, Pharmacokinetics, and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase 1A/1B Study

Locations:

ClinicalTrials.gov ID:

NCT04140526

ClinicalTrials.gov Link:

Clinical Trial BB1701

A First-in-Human, Open Label, Multiple Dose, Dose Escalation, and Cohort Expansion Phase I Study to Investigate the Safety, Tolerablity, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04257110

ClinicalTrials.gov Link:

Clinical Trial D9077C00001

A Phase 2 Open-Label, Multicenter Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-Stage (II-IIIA) NSCLC

Locations:

ClinicalTrials.gov ID:

NCT05061550

ClinicalTrials.gov Link:

Clinical Trial CINC280AUS12

A Phase 2 Trial of Neoadjuvant and Adjuvant Capmatinib in Participants with Stages IB-IIIA, N2, and Selected IIIB (T3N2 or T4N2) NSCLC with MET Exon 14 Skipping Mutation or High MET Amplification

Locations:

ClinicalTrials.gov ID:

NCT04926831

ClinicalTrials.gov Link:

Clinical Trial USOR 21320

A Phase 1/2 Open-Label Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutated, Metastatic NSCLC Who Have Progressed After Treatment with Osimertinib

Locations:

ClinicalTrials.gov ID:

NCT04486833

ClinicalTrials.gov Link:

Clinical Trial TTI-621-03

A Phase 1/2 Study of TTI-621 in Combination with Doxorubacin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma

Locations:

ClinicalTrials.gov ID:

NCT04996004

ClinicalTrials.gov Link:

Clinical Trial INBRX105

An Open-Label, Multicenter, First-in-Human Dose Escalation, Phase 1 Study of INBRX-105 and INBRX-105 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT03809624

ClinicalTrials.gov Link:

Clinical Trial HFB-301001-01

A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients with Advanced Solid Tumors

Locations:

Clinical Trial ASP1570

A Phase 1 Study of ASP1570 in Participants with Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05083481

ClinicalTrials.gov Link:

Clinical Trial ASP7517

A Phase 1/2, Open-Label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Known to Express WT1 Antigen

Locations:

ClinicalTrials.gov ID:

NCT04837196

ClinicalTrials.gov Link:

Clinical Trial PRJ1-3024

A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05159700

ClinicalTrials.gov Link:

Clinical Trial ES002023-1001

An Open-Label, Mulitcenter, First-in-Human, Dose Escalation, Phase 1 Study of ES002023 in Patients with Locally Advanced or Metastatic Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05075564

ClinicalTrials.gov Link:

Clinical Trial IMM2902-101

A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05076591

ClinicalTrials.gov Link:

Clinical Trial M21-404

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05029882

ClinicalTrials.gov Link:

Clinical Trial ZB131-101

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likley to Express CSP

Locations:

ClinicalTrials.gov ID:

NCT05074472

ClinicalTrials.gov Link:

Clinical Trial HFB200301-01

A Phase 1, Open-Label, Multi-Center, Dose Escalation and expansion study of HFB200301 (TNFR2 Agonist Antibody) in Adult Patients with Advanced Solid Tumors

Locations:

Clinical Trial HBI-2376-101

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Locations:

ClinicalTrials.gov ID:

NCT05163028

ClinicalTrials.gov Link:

Clinical Trial NVL-520-01

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and other Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05118789

ClinicalTrials.gov Link:

Clinical Trial CTIV1708

A Phase 1/2 Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 when Administered via Intratumoral Injection as a Single Agent and in Combination with Intravenous Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT04780217

ClinicalTrials.gov Link:

Clinical Trial BGB-A317-A1217-301

A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiation Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus CCRT Followed by Tislelizumab Versus CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable NSCLC

Locations:

ClinicalTrials.gov ID:

NCT04866017

ClinicalTrials.gov Link:

Clinical Trial STRO-002-GM2

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers).

Locations:

ClinicalTrials.gov ID:

NCT03748186

ClinicalTrials.gov Link:

Clinical Trial STK-012-101

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT05098132

ClinicalTrials.gov Link:

Clinical Trial M21-410

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab

Locations:

ClinicalTrials.gov ID:

NCT05005403

ClinicalTrials.gov Link:

Clinical Trial RLY-2608-101

A First-in-Human Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

Locations:

ClinicalTrials.gov ID:

NCT05216432

ClinicalTrials.gov Link:

Clinical Trial RTX-224-01

A Phase 1/2 Study of RTX-224 for the Treatment of Patients with Advanced Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT05219578

ClinicalTrials.gov Link:

Clinical Trial 516-010

A Two-Cohort, Two-Part, Phase 1, Multicenter, Open-Label, Fixed-Sequence, Drug-Drug Interaction with QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Tumors.

Locations:

ClinicalTrials.gov ID:

NCT04887194

ClinicalTrials.gov Link:

Clinical Trial BLU-701-1101

A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.

Locations:

ClinicalTrials.gov ID:

NCT05153408

ClinicalTrials.gov Link:

Clinical Trial NBF-006

A Phase 1/1b Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non-Small Cell Lung Cancer.

Locations:

ClinicalTrials.gov ID:

NCT03819387

ClinicalTrials.gov Link:

Clinical Trial SALA-002-EW16

A Phase I Trial of LSD1 Inhibitor Seclidemstat (SP-2577) with and without Topetecan and Cyclophosphamide in Patients with Relapsed or Refractory Ewing Sarcoma and Select Sarcomas

Locations:

ClinicalTrials.gov ID:

NCT03600649

ClinicalTrials.gov Link:

Clinical Trial EFT226-0002

A Phase 1/2 Open Label, Sequential Group, Dose Escalation and Cohort Expansion Sutdy Evaluating the Safety, PK, PD and Antitumor Activity of eFT226 in Subjects with Selected Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04092673

ClinicalTrials.gov Link:

Clinical Trial LOXO-RAS-20001

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutated Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04956640

ClinicalTrials.gov Link:

Clinical Trial MVR-T3011-003

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered via Intravenous Infusion as a Single Agent and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04780217

ClinicalTrials.gov Link:

Clinical Trial GO-007

A Screening Study for the Selection of Patients for Clinical Studies Targeting Tumor-Specific Antigens (Non-Interventional)

Locations:

ClinicalTrials.gov ID:

NCT03953235

ClinicalTrials.gov Link:

Clinical Trial VX15-2503-12

A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent, or Metastatic Squamous Cell Cancer of the Head and Neck

Locations:

ClinicalTrials.gov ID:

NCT 04815720

ClinicalTrials.gov Link:

Clinical Trial FW-2020-1

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumors.

Locations:

ClinicalTrials.gov ID:

NCT04731467

Clinical Trial KZR-261-101

A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects with Advanced Solid Malignancies

Locations:

ClinicalTrials.gov ID:

NCT05047536

ClinicalTrials.gov Link:

Clinical Trial ERAS-007-03

Phase 1b/2 Study of Agents Targeting the Mitogen Activated Protein Kinase Pathway in Patients with Advanced GI Malignancies

Locations:

ClinicalTrials.gov ID:

NCT05039177

ClinicalTrials.gov Link:

Clinical Trial MRG004A-001

“An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess
the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in
Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors”

Locations:

ClinicalTrials.gov ID:

NCT04843709

ClinicalTrials.gov Link:

Clinical Trial AVB500-PC-005

A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nabpaclitaxel
and Gemcitabine in Patients with Locally Advanced
or Metastatic Pancreatic Adenocarcinoma

Locations:

ClinicalTrials.gov ID:

NCT04983407

ClinicalTrials.gov Link:

Clinical Trial C4401001

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE
SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS,
AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED
OR METASTATIC TUMORS

Locations:

ClinicalTrials.gov ID:

NCT04881045

ClinicalTrials.gov Link:

Clinical Trial 20291

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects with Advanced Solid Tumors with KRAS G12C Mutation **MANY SUBPROTOCOLS FOR THIS TRIAL**

Locations:

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Clinical Trial 20289

A Phase I Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Locations:

ClinicalTrials.gov ID:

NCT04254107

ClinicalTrials.gov Link:

Clinical Trial 20305

An Open-Label, Phase 1b, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Efficacy of the Aryl Hydocarbon Receptor Inhibitor (AhRi) BAY 2416964 in Combination with Pembrolizumab in Participants with Advanced Tumors

Locations:

ClinicalTrials.gov ID:

NCT04999202

ClinicalTrials.gov Link:

Clinical Trial TWT-101

A First in Human, Phase 1/2 Study of CFI-402411, Hematopoeitic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advnanced Solid Malignancies

Locations:

ClinicalTrials.gov ID:

NCT04521413

ClinicalTrials.gov Link:

Clinical Trial TTX-030-002

A Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04306900

ClinicalTrials.gov Link:

Clinical Trial TPX-0022-01

A Phase I, Open-Label, Multicenter, First in Human Study of the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of TPX-0022, A Novel MET/CSF1R/SRC Inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations I MET

Locations:

ClinicalTrials.gov ID:

NCT03993873

ClinicalTrials.gov Link:

Clinical Trial RTX-24-01

Open-Label, Multicenter, First in Human Phase 1/2 Study of RTX-240 for the Treatment of Patients with Relapsed/Refractory or Locally Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04372706

ClinicalTrials.gov Link:

Clinical Trial DF6002-001

A Phase 1/2, First in Human, Multi-Part, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04423029

ClinicalTrials.gov Link:

Clinical Trial M19-037

A Phase I, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT03893955

ClinicalTrials.gov Link:

Clinical Trial NB-ND021 (NM21-1480)-101

Phase 1/2 Study of NM21-1480 (Anti-PD-L1/Anti-4-1BB/Anti-HAS Tri-Specific Antibody) in Adults with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04442126

ClinicalTrials.gov Link:

Clinical Trial CPO-100-US-101

A Phase I, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adults with Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04931823

ClinicalTrials.gov Link:

Clinical Trial D976MC00001

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Unresectable and or Mets Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology

Locations:

ClinicalTrials.gov ID:

NCT04639219

ClinicalTrials.gov Link:

Clinical Trial 20383

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Everolimus in Subjects with Advanced Solid Tumors with KRAS G12C Mutation

Locations:

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Clinical Trial KN 8701

A Phase 1/1b Open-Label, Multicenter, Two-Part Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-8701 in Subjects with BRAF Mutation Positive Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT04913285

ClinicalTrials.gov Link:

Clinical Trial TCTLR-101

Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of Transcon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Locations:

ClinicalTrials.gov ID:

NCT04799054

ClinicalTrials.gov Link:

Clinical Trial D6185C00001

An Open-Label, Multi-Drug, Biomarker-Directed, Multicenter Phase II Umbrella Study in Patients with NSCLC, Who Progressed on and Anti-PD-1/PD-L1 Containing Therapy

Locations:

ClinicalTrials.gov ID:

NCT03334617

ClinicalTrials.gov Link:

Clinical Trial BGB-A317-A1217-302

A Phase III, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination with Tislelizumab Compared to Pembrolizumab in Patients with Previously Untreated, PD-L1 Selected, and Locally Advanced, Unresectable or Metastatic NSCLC

Locations:

ClinicalTrials.gov ID:

NCT04746924

ClinicalTrials.gov Link:

Clinical Trial D910MC00001

Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy.

Locations:

Clinical Trial 20139

A Phase III, Randomized, Controlled, Multi-Center, 3 Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SOC Chemo Alone for the Treatment of Patients with EGFR Positive, Resectable NSCLC

Clinical Trial D910LC00001

A Phase III, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-Based Chemotherapy in Completely Resected Stage II-III NSCLC

Locations:

Clinical Trial ACT16146

Randomized, Open-Label Phase II Study of SAR408701 Combined with Pembrolizumab and Pembrolizumab Alone in Patients with CEACAM5 and PD-L1 Positive Advanced/Metastatic Non-Squamous NSCLC.

Locations:

ClinicalTrials.gov ID:

NCT04524689

ClinicalTrials.gov Link:

Clinical Trial 20270

Phase II Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced NSCLC with KRAS G12C Mutation

Locations:

ClinicalTrials.gov ID:

NCT04613596

ClinicalTrials.gov Link:

Clinical Trial 20384

A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG510 (pINN Sotorasib) in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced NSCLC with KRAS G12C Mutation

Locations:

Arlington Infusion Suite

Alexandria Office

Loudoun Office

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Clinical Trial U31402-A-U103

A Phase I Open-Label Study of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib in Subjects with Locally Advanced or Mets EGFR-Mutated NSCLC

Locations:

ClinicalTrials.gov ID:

NCT04676477

ClinicalTrials.gov Link:

Clinical Trial 61186372EDI1001

Phase I, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced NSCLC

Locations:

ClinicalTrials.gov ID:

NCT02609776

ClinicalTrials.gov Link:

Clinical Trial KL 264-01

A Phase I-II, First in Human Study of SKB264 in Patients with Locally Advanced Unresectable and Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies

Locations:

ClinicalTrials.gov ID:

NCT04152499

ClinicalTrials.gov Link:

Clinical Trial MRTX849-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C

Locations:

ClinicalTrials.gov ID:

NCT03785249

ClinicalTrials.gov Link:

Clinical Trial PCS6422G1-01

A Phase 1b Dose-Escalation Study of the Safety and Pharmacokinetics of Fixed-Dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors

ClinicalTrials.gov ID:

NCT04861987

ClinicalTrials.gov Link:

Clinical Trial 20310

A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS G12C

Locations:

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Clinical Trial 21194

A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib in Combination with MVASI and FOLFIRI and in Combination with MVASI and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS G12C Mutation

Locations:

ClinicalTrials.gov ID:

NCT04190135

Clinical Trial DS1062-A-U301

Phase 3 Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Locations:

ClinicalTrials.gov ID:

NCT04656652

ClinicalTrials.gov Link:

Clinical Trial 20344

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Locations:

ClinicalTrials.gov ID:

NCT04579380

ClinicalTrials.gov Link:

Clinical Trial 20331

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

Locations:

ClinicalTrials.gov ID:

NCT04620330

ClinicalTrials.gov Link:

Clinical Trial 18194

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Locations:

ClinicalTrials.gov ID:

NCT03748186

ClinicalTrials.gov Link:

Clinical Trial CLN-081-001

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Locations:

ClinicalTrials.gov ID:

NCT04036682

ClinicalTrials.gov Link:

Clinical Trial ZWI-ZW49-101

Locations:

ClinicalTrials.gov ID:

NCT03821233

ClinicalTrials.gov Link:

Clinical Trial 73841937NSC1001

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Locations:

ClinicalTrials.gov ID:

NCT04077463

ClinicalTrials.gov Link:

Clinical Trial M19-611

A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Locations:

ClinicalTrials.gov ID:

NCT04189614

ClinicalTrials.gov Link:

Clinical Trial APG-115-US-002

Locations:

ClinicalTrials.gov ID:

NCT03611868

ClinicalTrials.gov Link:

Clinical Trial KL26401

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies

Locations:

ClinicalTrials.gov ID:

NCT04152499

ClinicalTrials.gov Link:

Clinical Trial 19043

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)

Locations:

ClinicalTrials.gov ID:

NCT03964727

ClinicalTrials.gov Link:

Clinical Trial TPX-005-001

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locations:

ClinicalTrials.gov ID:

NCT03093116

ClinicalTrials.gov Link:

Clinical Trial ASTX295-01

Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

Locations:

ClinicalTrials.gov ID:

NCT03975387

ClinicalTrials.gov Link:

Clinical Trial 849-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Locations:

ClinicalTrials.gov ID:

NCT03785249

ClinicalTrials.gov Link:

Clinical Trial M14-239

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Locations:

ClinicalTrials.gov ID:

NCT03539536

ClinicalTrials.gov Link:

Clinical Trial C2321001

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Locations:

ClinicalTrials.gov ID:

NCT03460977

ClinicalTrials.gov Link:

Clinical Trial LOXO-RET-17001

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001

Locations:

ClinicalTrials.gov ID:

NCT03157128

ClinicalTrials.gov Link:

Clinical Trial Janssen 61186372EDI10051

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

Locations:

ClinicalTrials.gov ID:

NCT02609776

ClinicalTrials.gov Link:

Clinical Trial GO-003

An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine in Patients with Advanced Cancer

Locations:

Clinical Trial 17-167

A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Locations:

ClinicalTrials.gov ID:

NCT03447769

ClinicalTrials.gov Link: